TargetMol

Vazegepant hydrochloride

Product Code:
 
TAR-T8682
Product Group:
 
Inhibitors and Activators
Supplier:
 
TargetMol
Regulatory Status:
 
RUO
Shipping:
 
cool pack
Storage:
 
-20℃
1 / 1
❮❯

No additional charges, what you see is what you pay! *

CodeSizePrice
TAR-T8682-1mg1mg£158.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T8682-5mg5mg£262.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T8682-1mL1 mL * 10 mM (in DMSO)£349.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T8682-10mg10mg£353.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T8682-25mg25mg£548.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T8682-50mg50mg£752.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T8682-100mg100mg£1,010.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
Prices exclude any Taxes / VAT
How to order with us   Contact us
Stay in control of your spending. These prices have no additional charges, not even shipping!
* Rare exceptions are clearly labelled (only 0.14% of items!).
Multibuy discounts available! Contact us to find what you can save.
This product comes from: United States.
Typical lead time: 10-14 working days.
Contact us for more accurate information.
  • Further Information
  • Documents
  • References
  • Show All

Further Information

Bioactivity:
Vazegepant is the first intranasal gepant for the acute treatment of migraine and has announced a positive phase II/III study.
CAS:
1414976-20-7
Formula:
C36H47ClN8O3
Molecular Weight:
675.28
Pathway:
Neuroscience; GPCR/G Protein
Purity:
0.9956
SMILES:
Cl.CN1CCC(CC1)N1CCN(CC1)C(=O)[C@@H](Cc1cc(C)c2[nH]ncc2c1)NC(=O)N1CCC(CC1)c1cc2ccccc2[nH]c1=O
Target:
CGRP Receptor

References

Moreno-Ajona D , Abigail P?rez-Rodr?guez, Goadsby P J . Gepants, calcitonin-gene-related peptide receptor antagonists: what could be their role in migraine treatment?[J]. Current Opinion in Neurology, 2020, 33(3):1.